Clinical Proteomic Technologies for Cancer Initiative (CPTAC) Phase I
CPTAC Phase I 2006 - 2011, was developed to address the pre-analytical and analytical variability issues that are major barriers to the field of proteomics. These barriers were: (1) experimental design; (2) technological and technical aspects of protein identification; (3) variability related to biospecimens collection; (4) the processes of data acquisition, analysis, and reporting; (5) the lack of reproducible proteomic technologies; and (6) the lack of highly characterized and standardized reagents. See https://cptacdcc.georgetown.edu/cptac/study/list?scope=Phase+I for more information.
There are currently no biomarkers annotated for this protocol.